Literature DB >> 2470847

Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli.

J A Warner1, S P Peters, L M Lichtenstein, W Hubbard, K B Yancey, H C Stevenson, P J Miller, D W MacGlashan.   

Abstract

We have examined the release of histamine and LTC4 from purified human basophils challenged with several different stimuli, both physiological and nonphysiological. Basophils (n = 16) challenged with 0.1 micrograms/ml anti-IgE released 38 +/- 4% of their available histamine and 39 +/- 12 ng LTC4/10(6) basophils within 15-30 min. F-Met peptide (n = 8) caused the release of 54 +/- 8% histamine and 42 +/- 25 ng LTC4/10(6) basophils within a period of 2-5 min. C5a caused the release of 22 +/- 3% histamine from selected donors but failed to initiate any LTC4 release unless combined with D2O or 5 mM extracellular calcium. The two nonphysiological stimuli A23187 and TPA caused extensive histamine release, 67 +/- 8 and 82 +/- 11%, respectively, and while A23187 initiated a large and rapid release of leukotriene, TPA failed to release any LTC4 even when combined with D2O or 2-5 mM extracellular calcium. Increased concentrations of extracellular calcium enhanced anti-IgE and f-Met peptide induced release of LTC4 but inhibited the A23187 induced release of leukotriene. A single peak of immunoreactive leukotriene C4 that comigrated with the authentic standard was identified using HPLC followed by radioimmunoassay. No LTD4 or LTE4 could be detected. Purified human basophils incubated with 0.2 microM [3H]AA incorporated 290 pmol/10(6) cells, or 32 +/- 5% of the available label within 60 min. The [3H]AA was taken principally into the phospholipids (73 +/- 5%), with 20 +/- 3% as neutral lipid, and only 5 +/- 2% remaining as the free acid. Three phospholipid subclasses, phosphatidylcholine, PC (24 +/- 2%), phosphatidylinositol, PI (22 +/- 1%), and phosphatidylethanolamine, PE (15 +/- 3%), accounted for the majority of the incorporated [3H]AA while the remainder of the phospholipids accounted for less than 5% of the total cpm. HPLC analysis of the lipid mediators released during stimulation with 0.1 micrograms/ml anti-IgE revealed [3H]LTC4 (2.4 +/- 1.0%), [3H]5HETE (1.0 +/- 0.1%), unmetabolized [3H]AA (91 +/- 2%), and an unidentified peak (3.4 +/- 1.4%). The unknown metabolite eluted with the prostaglandins, was inhibited by indomethacin, and appeared to have a relatively high specific activity. It may thus represent an artifact of the labeling procedure rather than a novel basophil-derived prostaglandin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470847     DOI: 10.1002/jlb.45.6.558

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  5 in total

1.  Effect of R59022, an inhibitor of diacylglycerol kinase, on IgE-mediated histamine release from human lung mast cells and basophils.

Authors:  K L O'Keefe; J A Warner
Journal:  Agents Actions       Date:  1994-11

2.  FcεRI, but not FcγR, signals induce prostaglandin D2 and E2 production from basophils.

Authors:  Tsukasa Ugajin; Takahiro Satoh; Toru Kanamori; Kosuke Aritake; Yoshihiro Urade; Hiroo Yokozeki
Journal:  Am J Pathol       Date:  2011-06-25       Impact factor: 4.307

3.  An ultrastructural analysis of tumor-promoting phorbol diester-induced degranulation of human basophils.

Authors:  A M Dvorak; J A Warner; E Morgan; S Kissell-Rainville; L M Lichtenstein; D W MacGlashan
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

4.  Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils.

Authors:  Tomoyuki Bando; Setsuko Fujita; Naoko Nagano; Soichiro Yoshikawa; Yoshinori Yamanishi; Masashi Minami; Hajime Karasuyama
Journal:  Biochem Biophys Rep       Date:  2017-03-15

5.  Expression profiling of constitutive mast cells reveals a unique identity within the immune system.

Authors:  Daniel F Dwyer; Nora A Barrett; K Frank Austen
Journal:  Nat Immunol       Date:  2016-05-02       Impact factor: 25.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.